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Primary abnormalities in the dystrophin gene cause X-linked muscular dystrophy, a highly
progressive muscle wasting disorder of childhood. A spontaneous animal model of
Duchenne muscular dystrophy is the mdx mouse, which presents a highly interesting
phenotype that exhibits considerable variations in the degree of fiber degeneration
in different subtypes of muscles. The idea that aging exacerbates the dystrophic
mdx phenotype, as previously indicated by a large number of biochemical and cell
biological studies, was clearly confirmed by comparative muscle proteomics. Here we
outline recent findings of age-dependent changes in the dystrophin-deficient muscle
proteome and contrast these results with the previously established proteomic profile of
sarcopenic muscle. Besides comparable perturbations of various biochemical functions,
especially striking are similarities in the cellular stress response associated with a drastic
up-regulation of small αB-crystallin-like heat shock proteins. Hence, the comparison of
large-scale proteomic data sets of natural muscle aging with dystrophic sarcopenia
promises to shed light on the differential effect of sarcopenia of old age vs. senescent
abnormalities on a mutant dystrophic background.
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INTRODUCTION
A high degree of load bearing and the continuous strain of
excitation-contraction-relaxation cycles exert considerable physi-
cal tension on the peripheral structures of muscle fibers. In con-
junction with sarcolemmal integrin complexes and cytoskeletal
spectrin networks, the dystrophin-glycoprotein complex presents
a major stabilizing protein assembly that counter-acts poten-
tial contraction-induced rupturing of the muscle surface mem-
brane (Gumerson and Michele, 2011). The integral glycoprotein
β-dystroglycan forms the core of this plasmalemma-spanning
complex by interacting with the dystrophin isoform Dp427
on the inside of muscle fibers and concurrent binding to its
extracellular subunit α-dystroglycan on the outside of con-
tractile cells (Ibraghimov-Beskrovnaya et al., 1992). Since α-
dystroglycan is a receptor of the extracellular matrix protein
laminin and dystrophin acts as a cytoskeletal actin-binding pro-
tein, this complex structure confers flexibility to the muscle
periphery and also anchors signaling molecules and ion channels
within the sarcolemma region. Additional core members of the
dystrophin-associated protein complex are sarcoglycans, dystro-
brevins, syntrophins, and sarcospan (Ohlendieck, 1996; Ervasti,
2007).
In Duchenne muscular dystrophy, primary genetic abnor-
malities in the dystrophin gene cause the loss of the full-
length Dp427 isoform of this membrane cytoskeletal protein
(Hoffman et al., 1987) and the drastic reduction in all dystrophin-
associated glycoproteins (Ohlendieck et al., 1993). Destabilization
of sarcolemmal integrity results in an increased susceptibility to
membrane micro-rupturing and complex cellular dysregulations
(Rahimov and Kunkel, 2013), which play a central role in
calcium-dependent damage pathways in muscular dystrophy
(Allen et al., 2010). In this Perspective Article, the age-related
exacerbation of the dystrophic phenotype is discussed and new
pathobiochemical insights into dystrophinopathy outlined as
revealed from the proteomic profiling of senescent mdx mouse
muscles.
PATHOPHYSIOLOGICAL SUITABILITY OF THE mdx MOUSE
MODEL OF X-LINKED MUSCULAR DYSTROPHY
The mdx mouse is an internationally established animal model
of Duchenne muscular dystrophy that is characterized by (i)
a point mutation within exon 23 of the dystrophin gene,
(ii) loss of the Dp427 isoform due to the premature termi-
nation of the full-length dystrophin polypeptide chain, (iii)
reduction in all dystrophin-associated glycoproteins, (iv) gen-
eral muscle damage as indicated by elevated levels of serum
creatine kinase, (v) a high susceptibility to osmotic shock, (vi)
an increased vulnerability to contraction- or stretch-induced
injury, (vii) an enhanced cellular stress response, (viii) impaired
excitation-contraction coupling, (ix) a lowered calcium buffer-
ing capacity in the sarcoplasmic reticulum, and (x) a chronic
cytosolic calcium overload affecting rates of proteolysis (Banks
and Chamberlain, 2008). Although one has to take into account
the limitations of animal models for studying complex human
diseases (Partridge, 2013), the mdx mouse can be conveniently
used for determining basic pathophysiological mechanisms of
dystrophinopathy and testing new pharmacological strategies
or gene therapeutic approaches. This makes the dystrophic
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mdx mouse model an essential part of the overall strategy
to elucidate the molecular pathogenesis of X-linked muscu-
lar dystrophy and find novel treatment options to reverse
muscle degeneration in dystrophin-deficient fibers (De Luca,
2012).
It should be noted that the absence of dystrophin does
not result in the same downstream alterations in differ-
ent subtypes of mdx muscles and aging clearly worsens the
dystrophic phenotype. While limb muscles display segmen-
tal necrosis and moderate weakness, laryngeal and extraoc-
ular muscles exhibit minimal effects and the diaphragm is
severely dystrophic and functionally impaired in the mdx mouse
(Stedman et al., 1991). This makes the various subtypes of
mdx muscles extremely interesting for studying secondary abnor-
malities in dystrophinopathies and determining the detailed
molecular and cellular features of compensatory mechanisms.
Importantly, because the aged phenotype of the mdx diaphragm
and heart closely resemble the human pathology, senescent
mdx tissues present ideal model systems to determine the
underlying mechanisms of fiber alterations during progressive
skeletal muscle degeneration and muscular dystrophy-associated
cardiomyopathy.
WHAT PROTEOME-WIDE EFFECTS ARE ASSOCIATED WITH A
DEFICIENCY IN DYSTROPHIN ISOFORM DP427?
The combination of large-scale protein separation techniques,
such as two-dimensional gel electrophoresis and advanced liq-
uid chromatography, and high-resolution mass spectrometry
enable ultra-sensitive proteomic workflows (Altelaar and Heck,
2012). Over the last decade, mass spectrometry-based pro-
teomics has been applied to studying the dystrophin-glycoprotein
complex and the many downstream effects of dystrophin defi-
ciency in muscular dystrophy (for review see, Holland et al.,
2013a). Many of these investigations have focused on crude
cellular extracts from the mdx mouse model of dystrophinopa-
thy and the flow chart of Figure 1 outlines that the dys-
trophic mdx phenotype is characterized initially by moderate
changes in the muscle tissue proteome, followed by consid-
erably more severe proteome-wide changes in aged muscles
on a mutant dystrophic background. The proteomic profil-
ing of mildly dystrophic muscle subtypes revealed only very
few changes in extraocular and interosseus muscles (Lewis and
Ohlendieck, 2010; Carberry et al., 2013a). Segmental necrosis
in moderately affected young mdx leg muscles was shown to
be associated with changes in nucleotide metabolism (Ge et al.,
2003) and generally perturbed muscle protein expression lev-
els (Gardan-Salmon et al., 2011). Considerable changes in the
degree and number of proteins was revealed by the fluores-
cence two-dimensional difference in-gel electrophoretic analysis
of the adult mdx diaphragm muscle, which exhibits a variety
of alterations in proteins involved in muscle contraction, ion
homeostasis, nucleotide metabolism, the cellular stress response,
energy metabolism and sarcolemmal signaling (Doran et al.,
2006). Hence, dystrophin deficiency and the resulting collapse of
the linkage between the intracellular actin cytoskeleton and the
basal lamina triggers a variety of downstream modifications in
muscular dystrophy.
HOW DOES AGING AFFECT THE DYSTROPHIC mdx
PHENOTYPE?
The majority of proteomic surveys have focused on the acute
phase of dystrophic changes in young mdx muscles or stud-
ied mature mdx muscle tissues. Recently, several proteomic
investigations have also determined proteome-wide alterations
during aging of the mdx model of dystrophinopathy. This is
crucial, since aged mdx muscle exhibit pathological changes
that more closely resemble the human pathology, includ-
ing progressive contractile weakness due to the extensive loss
of myofibers and replacement by connective and fatty tis-
sue, abnormal signaling pathways, the appearance of branched
fibers that trigger mechanical weakening of the sarcolemma,
an impaired functional and structural recovery after injury
and a drastic decline in regenerative potential (Holland et al.,
2013a). The proteomic profiling of dystrophic sarcopenia has
clearly demonstrated an exacerbated phenotype of muscle
wasting.
The proteomic comparison of the senescent mdx diaphragm
vs. age-matched wild type resulted in the mass spectrometric
identification of 84 altered protein species. The new molecu-
lar insights into dystrophic changes in aged mdx mice indicated
severely impaired calcium buffering, drastically elevated levels
of cellular stress, cyto-structural alterations and metabolic dis-
turbances in dystrophin-deficient muscle tissue (Carberry et al.,
2013b). Although laminin is not affected in dystrophic skeletal
muscles, aged cardiac mdx muscles showed a drastic reduction
in laminin and nidogen (Holland et al., 2013b), which suggests
a disintegration of the basal lamina structure and cytoskele-
tal network in cardiac fibers that lack the Dp427 isoform of
dystrophin.
HOW DOES THE NATURAL AGING PROCESS AFFECT THE
MUSCLE PROTEOME?
Biological aging is a multi-factorial process and associated with a
large spectrum of physical ailments. The gradual loss of muscle
mass and contractile strength increases the risk of poor balance,
impaired mobility and frequent falling (Berger and Doherty,
2010). The systematic application of proteomics for studying
aging has revealed muscle fiber transitions and metabolic shifts
in senescent skeletal muscles (Piec et al., 2005; Gelfi et al.,
2006; Gannon et al., 2009). Although mitochondrial impair-
ments have been well documented to occur in aged human
muscle (Théron et al., 2014) and animal models of sarcope-
nia (Ibebunjo et al., 2013), a glycolytic-to-oxidative shift is
present in slower-twitching senescent muscles (O’Connell and
Ohlendieck, 2009). These changes cannot be considered primary
triggering factors of sarcopenia, but are most likely a patho-
physiological consequence of changes in the peripheral nervous
system and a higher susceptibility of fast vs. slow fibers to
age-related degeneration processes (for review, see Ohlendieck,
2011). A recent quantitative analysis of age-associated changes
in the mouse gastrocnemius muscle proteome revealed changes
in key calcium-handling proteins (Hwang et al., 2014), which
agrees with the idea of impaired excitation-contraction coupling
and disturbed ion homeostasis in sarcopenia (O’Connell et al.,
2008).
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FIGURE 1 | Age-related progression of pathophysiological abnormalities in dystrophin-deficient muscle.
COMPARISON OF SARCOPENIA OF OLD AGE vs.
DYSTROPHIC SARCOPENIA
Since both dystrophic sarcopenia and natural muscle senescence
are characterized by a progressive loss of contractile tissue mass,
elevated levels of fibrosis, a decline in the number of satellite cells,
a drastically increased stress response and abnormal cellular sig-
naling, it is interesting to determine whether these pathological
similarities are reflected by analogous proteome-wide changes.
The comparison of proteomic data sets from the analysis of mus-
cular dystrophy vs. sarcopenia suggests that the pathobiochemical
signature of certain damage or adaptation pathways is compara-
ble, but that the molecular pathogenesis of both processes differs
with respect to the degree of unilateral shifts in fiber types or
energy metabolism. Both age-related processes show a disturbed
abundance of proteins involved in excitation-contraction cou-
pling, calcium homeostasis, cellular signaling cascades, the mus-
cle contraction-relaxation cycle and the cellular stress response.
For example, the expression of small heat shock proteins, such
as αB-crystallin and some of its HSPB isoforms, is drastically
increased in both natural muscle aging and dystrophic sarcopenia
(Doran et al., 2006, 2007). Both types of skeletal muscle wast-
ing are associated with altered levels of key enzymes involved
in glycolysis, the citric acid cycle and oxidative phosphorylation
(Piec et al., 2005; Doran et al., 2006, 2008). However, mus-
cular dystrophy exhibits a generally perturbed abundance of
metabolic enzymes, while the proteomic profiling of sarcopenia of
old age clearly indicates a glycolytic-to-oxidative metabolic shift
and concomitant fast-to-slow transformation on the level of the
actomyosin apparatus (Ohlendieck, 2011). Figure 2 outlines the
findings of the proteomic profiling of sarcopenia of old age vs.
dystrophic sarcopenia.
CONCLUSION
The application of proteomics for studying muscular dystrophy
and aging has allowed the unbiased and hypothesis-generating
analysis of the age-associated progression of the dystrophic phe-
notype. The combination of large-scale protein separation, high-
throughput mass spectrometry and advanced bioinformatics has
enabled the field of applied myology to evaluate global changes
in muscle protein constellations. In both, cellular biogerontology
and muscular dystrophy research, the identification of molecular
changes in pathological tissues plays a crucial role in improv-
ing our detailed understanding of the fiber wasting process, and
might also be helpful in refining diagnostic procedures, prognos-
tic methodology and therapeutic approaches. Proteomic profiling
has shown that the degree of change and the number of affected
muscle proteins drastically increase in an age-related fashion in
various subtypes of muscles in the dystrophic mdx mouse. This
pathobiochemical exacerbation justifies the new term “dystrophic
sarcopenia” for describing the age-related progressive phenotype
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FIGURE 2 | Overview of proteome-wide alterations in the muscle tissue during sarcopenia of old age vs. dystrophic sarcopenia.
of dystrophinopathy. It remains to be determined what exact role
abnormalities in the nervous system play in dystrophinopathies
and whether neuronal impairments increase with aging (Waite
et al., 2012). In contrast to proteome-wide alterations during
natural muscle aging, which is characterized by relatively uni-
lateral metabolic and fiber type shifting, dystrophin-deficient
fibers exhibit a more generally disturbed protein expression pat-
tern during aging without distinct metabolic adaptations. Thus,
sarcopenia appears to be more closely related to a differential
susceptibility of individual fiber types to muscular atrophy, caus-
ing an overall fast-to-slow transition process, as compared to
aged dystrophic muscle. Overall, the pathomechanisms of natural
muscle aging and dystrophic sarcopenia share certain molecular
and cellular modifications, but appear to differ in the fiber type
specificity of their pathological susceptibility.
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